English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Currently there is no vaccine available in use against any form of leishmaniases worldwide.To assess potential of a live-attenuated Leishmania major promastigates, for protection against a challenge infection with L. major in BALB/c mice.A laboratory based study.Study was carried out at Centre for Biotechnology Research and Development, Kenya Medical Research Institute, Nairobi.The greatest protection against challenge with L. major was seen in mice immunised with live parasites (P < 0.001) compared to vaccinations with heat killed or soluble antigens. In general, immunised mice produced high level of antileishmanial antibodies and T cell stimulation to their respective antigens.Our live-attenuated parasites produced by serial sub-culture of L. major parasites 118 times showed the capacity to induce appropriate cell-mediated immune responses and protection against L. major infection in BALB/c mice. Data also suggests that these parasites do not revert to virulence when injected subcutaneously in mice.

east african medical journal

Vaccinations with live-attenuated &lt;i&gt;Leishmania major&lt;/i&gt; promastigotes and challenge infection with &lt;i&gt;L. major&lt;/i&gt; in balb/c mice